Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle

Journal of Clinical Investigation

Volumn 101, Issue 12, 1998, Pages 2842-2850

  Gill, Jagjit S ^a   Windebank, Anthony J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Nerve growth factor; Neurotrophins; Platinum neurotoxicity

Indexed keywords

CISPLATIN; CYCLIN D1; DNA FRAGMENT; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DNA ADDUCT; IMMUNOBLOTTING; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE CELL; SPINAL GANGLION;

EID: 0032526263     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1130     Document Type: Article

References (83)

1. Von Hoff, D.D., R. Schilsky, C.M. Reichert, R.L. Reddick, M. Rozencweig, R.C. Young, and F.M. Muggia. 1979. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat. Rep. 63:1527-1531.
2. Mollman, J.E. 1990. Cisplatin neurutoxicity. N. Engl. J. Med. 322:126-127.
3. Walsh, T.J., A.W. Clark, I.M. Parhad, and W.R. Green. 1982. Neurotoxic effects of cisplatin therapy. Arch. Neurol. 39:719-720.
4. Calabresi, P., and B.A. Chabner. 1996. Chemotherapy of neoplastic diseases. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, and A.G. Gilman, editors. McGraw-Hill, New York. 1225-1287.
5. Gregg, R.W., J.M. Molepo, V.J.A. Monpetit, N.Z. Mikael, D. Redmond, M. Gadia, and D.J. Stewart. 1992. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol. 10:795-803.
6. Krarup-Hansen, A., K. Fugleholm, S. Helweg-Larsen, E.N. Hauge, H. Schmalbruch, W. Trojaborg, and C. Krarup. 1993. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 116:1017-1041.
7. Fu, K.K., E.F.Y. Kai, and C.K. Leung. 1995. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J. Clin. Pharm. Ther. 20:167-172.
8. McKeage, M.J. 1995. Comparative adverse effect profiles of platinum drugs. Drug Saf. 13:228-244.
9. Ozols, R.F., Y. Ostchega, C.F. Myers, and R.C. Young. 1985. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J. Clin. Oncol. 3: 1246-1250.
10. Thompson, S.W., L.E. Davis, M. Kornfeld, R.D. Hilgers, and J.C. Standefer. 1984. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 54:1269-1275.
11. Roelofs, R.I., W. Hrushesky, J. Rogin, and L. Rosenberg. 1984. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 34:934-938.
12. Grunberg, S.M., S. Sonka, L.L. Stevenson, and F.M. Muggia. 1989. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother. Pharmacol. 25:62-64.
13. Mollman, J.E., W.M. Hogan, D.J. Glover, and L.F. McCluskey. 1988. Unusual presentation of cis-platinum neuropathy. Neurology. 38:488-490.
14. Machover, D., E. Diaz-Rubio, A. De Gramont, A. Schilf, J.-J. Gastiaburu, S. Brienza, M. Itzhaki, G. Metzger, D. N'Daw, J. Vignoud, et al. 1996. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:95-98.
15. Lévi, F., R. Zidani, J.-L. Misset, and the International Organization for Cancer Chronotherapy. 1997. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancer. 350:681-686.
16. Siddiqui, N., A.V. Boddy, H.D. Thomas, N.P. Bailey, L. Robson, M.J. Lind, and A.H. Calvert. 1997. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br. J. Cancer. 75:287-294.
17. Cowan, J.D., M.S. Kies, J.L. Roth, and R.P. Joyce. 1980. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum(II): a preliminary report. Cancer Treat. Rep. 64:1119-1122.
18. Cavaletti, G., G. Bogliun, L. Marzorati, G. Tredici, N. Colombo, G. Parma, and M.D. Miceli. 1994. Long-term peripheral neurotoxicity of cisplatin in patients wilh successfully treated epithelial ovarian cancer. Anticancer Res. 14:1287-1292.
19. Apfel, S.C., J.C. Arezzo, L. Lipson, and J.A. Kessler. 1992. Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 31:76-80.
20. Hamers, F.P.T., J.H. Brakkee, E. Cavalletti, M. Tedeschi, L. Marmonti, G. Pezzoni, J.P. Neijt, and W.H. Gispen. 1993. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 53:544-549.
21. Cavaletti, G., C. Minoia, M. Schieppati, and G. Tredici. 1994. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int. J. Radiol. Oncol. Biol. Phys. 29:771-776.
22. Gerritsen van der Hoop, R., F.P.T. Hamers, J.P. Neijt, H. Veldman, W.H. Gispen, and F.G.I. Jennekens. 1994. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J. Neurol. Sci. 126:109-115.
23. 4-9. Ann. Neurol. 36:284a. (Abstr.)
24. Cece, R., M.G. Petruccioli, G. Cavaletti, I. Barajon, and G. Tredici. 1995. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol. Histopathol. 10: 837-845.
25. Tomiwa, K., C. Nolan, and J.B. Cavanagh. 1986. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol. (Berl). 69:295-308.
26. Cavaletti, G., G. Tredici, P. Marmiroli, D. Fabbrica, and M. Braga. 1994. Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. In Vivo. 8:313-316.
27. Barajon, I., M. Bersani, M. Quartu, M. Del Fiacco, G. Cavaletti, J.J. Holst. and G. Tredici. 1996. Neuropeptides and morphological changes in cisplalin-induced dorsal root ganglion neuronopathy. Exp. Neurol. 138:93-104.
28. Hayakawa, K., G. Sobue, T. Itoh, and T. Mitsuma. 1994. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci. 55:519-525.
29. Konings, P.N.M., W.K. Makkink, A.M.L. van Delft, and G.S.F. Ruigt. 1994. Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res. 640:195-204.
30. Windebank, A.J., A.G. Smith, and J.W. Russell. 1994. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology. 44:488-494.
31. Boekelheide, K., M.E. Arcila, and J. Eveleth. 1992. cis-Diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics. Toxicol. Appl. Pharmacol. 116:146-151.
32. 4-9 on neural transport in cisplatin-induced neurotoxicity. Brain Res. 676:258-267.
33. Tredici, G., G. Cavaletti, M.G. Petruccioli, D. Fabbrica, M. Tedeschi, and P. Venturino. 1994. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology. 15:701-704.
34. Cascinu, S., L. Cordella, E. Del Ferro, M. Fronzoni, and G. Catalano. 1995. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol. 13:26-32.
35. Treskes, M., and W.J.F. van der Vijgh. 1993. WR2721 us a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 33:93-106.
36. Capizzi, R.L. 1994. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin. Oncol. 21:8-15.
37. Gispen, W.H., F.P.T. Hamers, C.J. Vecht, F.G.I. Jennekens, and J.P. Neyt. 1992. ACTH/MSH like peptides in the treatment of cisplatin neuropathy. J. Steroid Biochem. Mol. Biol. 43:179-183.
38. Hol, E.M., W.H. Gispen, and P.R. Bär. 1995. ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Peptides. 16:979-993.
39. Malgrange, B., P. Delrée, J.M. Rigo, H. Baron, and G. Moonen. 1994. Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J. Neurosci. Methods. 53: 111-122.
40. Gao, W.-O., N. Dybdal, N. Shinsky, A. Murnane, C. Schmelzer, M. Siegel, G. Keller, F. Hefti, H.S. Phillips, and J.W. Winslow. 1995. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. 38:30-37.
41. Schmidt, Y., J.W. Unger, I. Bartke, and R. Reiter. 1995. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp. Neurol. 132:16-23.
42. Zheng, J.L., R.R. Stewart, and W.O. Gao. 1995. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J. Neurosci. 15:5079-5087.
43. Zheng, J.L., R.R. Stewart, and W.-Q. Gao. 1995. Neurotrophin-4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins. J. Neurobiol. 28:330-340.
44. Windebank, A.J., and J.F. Poduslo. 1986. Neuronal growth factors produced by adult peripheral nerve after injury. Brain Res. 385:197-200.
45. Batistatou, A., and L.A. Greene. 1993. Internucleosomal DNA cleavage and neuronal cell survival/death. J. Cell Biol. 122:523-532.
46. Lucidi-Phillipi, C.A., D.O. Clary, L.F. Reichardt, and F.H. Gage. 1996. TrkA activation is sufficient to rescue axotomized cholinergic neurons. Neuron. 16:653-663.
47. Gill, J.S., D.C. Connolly, M.J. McManus, N.J. Maihle, and A.J. Windebank. 1996. Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J. Neurochem. 66:963-972.
48. Nicholson, D.W., A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, Y.A. Lazebnik, et al. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:37-43.
49. Jayadev, S., B. Liu, A.E. Bielawska, J.Y. Lee, F. Nazaire, M.Y. Pushkareva, L.M. Obeid, and Y.A. Hannun. 1995. Role for ceramide in cell cycle arrest. J. Biol. Chem. 270:2047-2052.
50. Reed, E., M. Poirier, R.C. Young, and R.F. Ozols. 1988. High dose cisplatin with hypertonic saline: toxicity and therapeutic results. In Organ Directed Toxicities of Anti-Cancer Drugs. Hacher, M.P., J.S. Lazo, and T.R. Tritton, editors. Matinous Nighoff, Boston. 203-213.
51. Reed, E., S. Sauerhoff, and M.C. Poirier. 1988. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure. A novel use of graphite furnace spectrometry. Atom. Spectro. 9:93-95.
52. Reed, E., and K.W. Kohn. 1990. Platinum analogues. In Cancer Chemotherapy: Principles and Practice. Chabner, B.A. and J.M. Collins, editors. J.B. Lippincott Co., Philadelphia. 465-490.
53. Huang, H., L. Zhu, B.R. Reid, G.P. Drobny, and P.B. Hopkins. 1995. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 270:1842-1845.
54. Powell, S.N., and E.H. Abraham. 1993. The biology of radioresistance: similarities, differences and interactions with drug resistance. Cytotechnology. 12:325-345.
55. 2/M when it is transactivation defective. EMBO J. 14:4994-5005.
56. Enoch, T., and C. Norbury. 1995. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem. Sci. 20:426-430.
57. Weinstein, I.B. 1996. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J. Cell. Biochem. Suppl. 25:23-28.
58. Fisher, R.P. 1997. CDKs and cyclins in transition(s). Curr. Opin. Genet. Dev. 7:32-38.
59. Elledge, S.J., and J.W. Harper. 1994. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6:847-852.
60. 1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
61. Sherr, C.J. 1995. D-type cyclins. Trends Biochem. Sci. 20:187-190.
62. Hengst, L., V. Dulic, J.M. Slingerland, E. Lees, and S.I. Reed. 1994. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA. 91:5291-5295.
63. Nobori, T., K. Miura, D.J. Wu, A. Lois, K. Takabayashi, and D.A. Carson. 1994. Deletions of the cyclin-dcpendent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:753-756.
64. De Luca, A., V. Esposito, A. Baldi, and A. Giordano. 1996. The retinoblastoma gene family and its role in proliferation, differentiation and development. Histol. Histopathol. 11:1029-1034.
65. Giordano, A., and H.E. Kaiser. 1996. The retinoblastoma gene: its role in cell cycle and cancer. In Vivo. 10:223-227.
66. Sidle, A., C. Palaty, P. Dirks, O. Wiggan, M. Kiess, R.M. Gill, A.K. Wong, and P.A. Hamel. 1996. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit. Rev. Biochem. Mol. Biol. 31:237-271.
67. Lees, J.A., K.J. Buchkovich, D.R. Marshak, C.W. Anderson, and E. Harlow. 1991. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 10:4279-4290.
68. DeCaprio, J.A., Y. Furukawa, F. Ajchenbaum, J.D. Griffin, and D.M. Livingston. 1992. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl. Acad. Sci. USA. 89:1795-1798.
69. Hatakeyama, M., R.A. Herrera, T. Makela, S.F. Dowdy, T. Jacks, and R. A. Weinberg. 1994. The cancer cell and the cell cycle clock. Cold Spring Harbor Symp. Quant. Biol. 59:1-10.
70. Hinds, P.W., S.F. Dowdy, E.N. Eaton, A. Arnold, and R.A. Weinberg. 1994. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA. 91:709-713.
71. Dowdy, S.F., P.W. Hinds, K. Louie, S.I. Reed, A. Arnold, and R.A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell. 73:499-511.
72. Motokura, T., and A. Arnold. 1993. Cyclin D and oncogenesis. Curr. Opin. Genet. Dev. 3:5-10.
73. Lee, E.Y.-H.P., N. Hu, S.-S.F. Yuan, L.A. Cox, A. Bradley, W.-H. Lee, and K. Herrup. 1994. Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev. 8:2008-2021.
74. Almasan, A., Y. Yin, R.E. Kelly, E.Y.-H.P. Lee, A. Bradley, W. Li, J.R. Bertino, and G.M. Wahl. 1995. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc. Natl. Acad. Sci. USA. 92:5436-5440.
75. Almasan, A., S.P. Linke, T.G. Paulson, L.-C. Huang, and G.M. Wahl. 1995. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev. 14:59-73.
76. Freeman, R.S., S. Estus, and E.M. Johnson, Jr. 1994. Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin DI during programmed cell death. Neuron. 12:343-355.
77. Ferrari, G., C.Y.I. Yan, and L.A. Greene. 1995. N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J. Neurosci. 15:2857-2866.
78. Farinelli, S.E., and L.A. Greene. 1996. Cell cycle blockers mimosine. ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci. 16:1150-1162.
79. Kranenburg, O., A.J. van der Eb, and A. Zantema. 1996. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBOJ. 15:46-54.
80. Park, D.S., S.E. Farinelli, and L.A. Greene. 1996. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J. Biol. Chem. 271:8161-8169.
81. Park, D.S., B. Levine, G. Ferrari, and L.A. Greene. 1997. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J. Neurosci. 17:8975-8983.
82. Cavaletti, G., D. Fabbrica, O. De Negri, C. Minoia, L. Frattola, and G. Tredici. 1998. A model of chronic administration of carboplatin to evaluate its effect on the peripheral nervous system of the rat. Toxicol. Appl. Pharmacol. In press.
83. Baslo, M.B., J.S. Gill, and A.J. Windebank. 1997. Rapid prediction of potential neurotoxicity of novel cisplatin analogs. Neurology. 48:319a. (Abstr.)